Last reviewed · How we verify
Liraglutide combined with metformin
At a glance
| Generic name | Liraglutide combined with metformin |
|---|---|
| Also known as | Victoza®, Novo Nordisk |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Metabolic Surgery for Atrial Fibrillation Elimination (PHASE4)
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (PHASE4)
- HbA1c Variability in Type II Diabetes (NA)
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes (PHASE3)
- Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients (PHASE4)
- Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility (PHASE3)
- A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) (PHASE3)
- Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liraglutide combined with metformin CI brief — competitive landscape report
- Liraglutide combined with metformin updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI